Shenzhenlubris Pharmaceuticals Co (SZSE:002294) Long-Term Capital Lease Obligation : ¥8 Mil (As of Mar. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Shenzhenlubris Pharmaceuticals Co Long-Term Capital Lease Obligation?

Shenzhenlubris Pharmaceuticals Co's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥8 Mil.

Shenzhenlubris Pharmaceuticals Co's quarterly Long-Term Capital Lease Obligation declined from Sep. 2023 (¥21 Mil) to Dec. 2023 (¥13 Mil) and declined from Dec. 2023 (¥13 Mil) to Mar. 2024 (¥8 Mil).

Shenzhenlubris Pharmaceuticals Co's annual Long-Term Capital Lease Obligation increased from Dec. 2021 (¥9 Mil) to Dec. 2022 (¥20 Mil) but then declined from Dec. 2022 (¥20 Mil) to Dec. 2023 (¥13 Mil).

Shenzhenlubris Pharmaceuticals Co Long-Term Capital Lease Obligation Historical Data

The historical data trend for Shenzhenlubris Pharmaceuticals Co's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shenzhenlubris Pharmaceuticals Co Long-Term Capital Lease Obligation Chart

Shenzhenlubris Pharmaceuticals Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

7.29

9.11

19.58

12.54

Shenzhenlubris Pharmaceuticals Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															19.55	16.46	21.39	12.54	8.07

Shenzhenlubris Pharmaceuticals Co (SZSE:002294) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Shenzhenlubris Pharmaceuticals Co Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Shenzhenlubris Pharmaceuticals Co's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Shenzhenlubris Pharmaceuticals Co (SZSE:002294) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Shenzhen Salubris Pharmaceuticals Co Ltd (SZSE:002294) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

1901 Chuangzhan Center, 6007 Shennan Road, Futian District, Shenzhen, CHN

Website

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co Ltd is a pharmaceutical company dedicated to the research, development, and sale of medical products for cardiovascular diseases, cephalous antibiotics, and bone resorption inhibitors. Its products mainly focused on the areas of cardio-cerebral vascular disease, diabetes, and complications, anti-tumor, and orthopedics, Its business lines include high-end chemical drugs, innovative biological drugs, and medical devices. Its businesses are located in China, the United States, Germany, France, and Japan, and other global countries and regions.

Executives

Yan Jie	Directors, executives
Yang Jian Feng	Secretary, Director
Zhao Song Ping	Executives
Liu Jun	Executives
Li Ai Zhen	Supervisors
Chen Ping	Executives
Ye Cheng Hai	Director
Lu Feng	Executives, directors
Chen Qiong Xing	Supervisors
Li Ying Hui	Supervisors
Pan Ling Man	Independent director
Zhang Zhong Xing	Executives

Shenzhenlubris Pharmaceuticals Co (SZSE:002294) Headlines

No Headlines